FAP-targeted PET imaging using 68Ga-FAPI enables early detection of myocardial fibrosis. Combined PET/CMR provides comprehensive cardiac assessment without extra radiation. This advanced imaging approach improves diagnosis and personalized treatment for better patient outcomes.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria:
* Participants must have a confirmed clinical diagnosis of cardiovascular disease by a cardiologist, based on genetic testing, family history, and comprehensive clinical evaluation including physical examination, echocardiography, and when indicated, cardiac MRI findings.
* Age requirement: \>18 years.
* Patients should demonstrate stable cardiovascular status without significant changes in symptoms, treatment, or clinical findings for a specified pre-enrollment period.
* Participants must be capable of providing informed consent and willing to adhere to all study requirements, including follow-up procedures.
Exclusion Criteria:
* History of malignancy
* Documented cardiovascular diseases, including coronary artery disease, myocardial infarction, or related conditions
* Implanted metallic devices (e.g., pacemakers, aneurysm clips) or other MRI-incompatible medical prostheses
* Claustrophobia
* Pregnancy or lactation
* Known hypersensitivity to gadolinium-based contrast agents
* Renal impairment (eGFR \<30 mL/min/1.73m² by CKD-EPI equation)
Primary outcome measure(s)
CE-CMR — After the patient completes the scan, an average of 2 days. Left ventricular wall thickness was quantified on short-axis cine images using the MR cardiac analysis software .
CE-MRI — After the patient completes the scan, an average of 2 days. Left ventricular ejection fraction (LVEF) was calculated from short-axis cine images using the cardiac MR analysis software.
PET — After the patient completes the scan, an average of 2 days. The maximum standardized uptake value (SUVmax) was calculated for each myocardial segment.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.